Known targets — ChEMBL curated mechanism
ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Methylamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | CA1 | P00915 | 3/20 | 0.58 |
| ▸ | CA2 | P00918 | 3/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | CA12 | O43570 | 2/20 | 0.58 |
| ▸ | CA9 | Q16790 | 2/20 | 0.58 |
| ▸ | CA3 | P07451 | 1/20 | 0.58 |
| ▸ | CA6 | P23280 | 1/20 | 0.58 |
| ▸ | CA5A | P35218 | 1/20 | 0.58 |
| ▸ | CA7 | P43166 | 1/20 | 0.58 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.58 |
| ▸ | NT5E | P21589 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrazine SCHEMBL8861759 | 0.95 | ALDH1A1 (0.58) | ALDH1A1CA1CA2TSHRCA12 | |
| Hydroxyamine SCHEMBL599912 | 0.95 | ALDH1A1 (0.58) | ALDH1A1CA1CA2TSHRCA12 | |
| SCHEMBL5068661 | 0.95 | GAA (0.62) | ALDH1A1CA1CA2TSHRCA12 | |
| SCHEMBL31313 | 0.95 | GAA (0.62) | ALDH1A1CA1CA2TSHRCA12 | |
| SCHEMBL29991938 | 0.95 | GAA (0.62) | ALDH1A1CA1CA2TSHRCA12 | |
| P-Xylene SCHEMBL8660591 | 0.95 | GAA (0.62) | ALDH1A1CA1CA2TSHRCA12 | |
| SCHEMBL1705904 | 0.95 | GAA (0.62) | ALDH1A1CA1CA2TSHRCA12 | |
| SCHEMBL34 | 0.95 | GAA (0.62) | ALDH1A1CA1CA2TSHRCA12 | |
| SCHEMBL11432043 | 0.95 | GAA (0.62) | ALDH1A1CA1CA2TSHRCA12 | |
| SCHEMBL11691939 | 0.93 | ALDH1A1 (0.56) | ALDH1A1CA1CA2TSHRCA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110256403-B | Method for preparing artificial synthetic nicotine | 深圳市馨艺坊生物科技有限公司 | 2020-06-19 | — | — | CN | claimed |
| US-11654443-B2 | Mineral processing | CIDRA MINERALS PROCESSING INC. (US) | 2023-05-23 | — | — | US | disclosed |
| CN-110256403-B | Method for preparing artificial synthetic nicotine | 深圳市馨艺坊生物科技有限公司 | 2020-06-19 | — | — | CN | disclosed |
| US-10618866-B2 | Method for synthesising partially N-hydroxyethylated tertiary 1,6-hexanediamines | IFP Energies Nouvelles (FR) | 2020-04-14 | — | — | US | disclosed |
| US-20190002392-A1 | IMPROVED METHOD FOR SYNTHESISING PARTIALLY N-HYDROXYETHYLATED TERTIARY 1,6-HEXANEDIAMINES | IFP Energies Nouvelles (FR) | 2019-01-03 | — | — | US | disclosed |
| WO-2013122760-A1 | COATINGS HAVING ENHANCED CORROSION PERFORMANCE AND METHODS OF USING THE SAME | MACDERMID ACUMEN, INC. (US) | 2013-08-22 | — | — | WO | disclosed |
| US-8501967-B2 | Process for the preparation of enantiomerically pure 1-substituted-3-aminoalcohols | LONZA AG (CH) | 2013-08-06 | — | — | US | disclosed |
| US-20120316350-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY PURE 1-SUBSTITUTED-3-AMINOALCOHOLS | LONZA AG (CH) | 2012-12-13 | — | — | US | disclosed |
| US-8258338-B2 | Process for the preparation of enantiomerically pure 1-substituted-3-aminoalcohols | LONZA AG (CH) | 2012-09-04 | — | — | US | disclosed |
| US-20090156833-A1 | Process for the Preparation of Enantiomerically Pure 1-Substituted-3-Aminoalcohols | LONZA AG (CH) | 2009-06-18 | — | — | US | disclosed |
| EP-0690715-A1 | TOPICAL AND SYSTEMIC APPLICATION OF BUSPIRONE OR DERIVATIVES THEREOF FOR TREATMENT OF PATHOLOGICAL CONDITIONS ASSOCIATED WITH IMMUNE RESPONSES | Beth Israel Hospital Association (US) | 1996-01-10 | — | — | EP | disclosed |
| WO-1994022448-A1 | TOPICAL AND SYSTEMIC APPLICATION OF BUSPIRONE OR DERIVATIVES THEREOF FOR TREATMENT OF PATHOLOGICAL CONDITIONS ASSOCIATED WITH IMMUNE RESPONSES | BETH ISRAEL HOSPITAL ASSOCIATION (US) | 1994-10-13 | — | — | WO | disclosed |
| EP-0461320-B1 | In mold coating compositions | GENCORP INC (US) | 1994-03-09 | — | — | EP | disclosed |
| EP-0461320-A1 | In mold coating compositions | GENCORP INC. (US) | 1991-12-18 | — | — | EP | disclosed |
| EP-0410976-A4 | HEAT STABLE QUATERNIZED LACTAMS HAVING OXYLATED SULFUR ANIONS | — | 1991-10-16 | — | — | EP | disclosed |
| EP-0410976-A1 | HEAT STABLE QUATERNIZED LACTAMS HAVING OXYLATED SULFUR ANIONS | GAF CHEMICALS CORPORATION (US) | 1991-02-06 | — | — | EP | disclosed |
| EP-0362459-A1 | Polyacrylate polymers utilizing substituted urea retarder | Zeon Chemicals USA, Inc. (US) | 1990-04-11 | — | — | EP | disclosed |
| EP-0340408-A1 | Process for the preparation of 2-hydroxy-4-(2'-hydroxyethoxy)-benzophenones | BASF Aktiengesellschaft (DE) | 1989-11-08 | — | — | EP | disclosed |
| WO-1989010358-A1 | HEAT STABLE QUATERNIZED LACTAMS HAVING OXYLATED SULFUR ANIONS | GAF CHEMICALS CORPORATION (US) | 1989-11-02 | — | — | WO | disclosed |
| EP-0309794-A2 | No-post-cure method of curing polyacrylate polymers | Zeon Chemicals USA, Inc. (US) | 1989-04-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190002392-A1 | IMPROVED METHOD FOR SYNTHESISING PARTIALLY N-HYDROXYETHYLATED TERTIARY 1,6-HEXANEDIAMINES | BHMT2, DNMT1, DNMT3A | ALDH1A1 313/4885CA1 3626/4885CA2 4700/4885 |
| US-20120316350-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY PURE 1-SUBSTITUTED-3-AMINOALCOHOLS | CYP2S1, AKR1C3, AKR1B10 | ALDH1A1 99/4885CA1 2629/4885CA2 2156/4885 |
| US-20090156833-A1 | Process for the Preparation of Enantiomerically Pure 1-Substituted-3-Aminoalcohols | CYP2S1, AKR1C3, ADSL | ALDH1A1 122/4885CA1 1994/4885CA2 1402/4885 |
| US-10618866-B2 | Method for synthesising partially N-hydroxyethylated tertiary 1,6-hexanediamines | BHMT2, DNMT1, HNMT | ALDH1A1 240/4885CA1 3693/4885CA2 4732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.